Actinobacillus Pleuropneumoniae (APP)

Actinobacillus pleuropneumoniae (APP) infection is a severe bacterial respiratory disease of swine that causes significant morbidity, mortality, and economic losses in pig production systems worldwide. This highly contagious pathogen produces a characteristic hemorrhagic necrotizing pneumonia with fibrinous pleuritis that can cause sudden death in affected pigs. The disease occurs in acute, subacute, and chronic forms, with the acute presentation being particularly devastating as it can kill seemingly healthy pigs within hours of the first clinical signs appearing.

APP affects swine populations globally and is considered one of the most important bacterial respiratory pathogens in modern pig production. The organism is widespread in most swine-producing regions, with herd prevalence varying by geographic area and management system. The disease is particularly problematic in intensive production systems where high stocking densities, mixing of pigs from different sources, and environmental stressors create conditions favoring disease transmission and expression. Growing and finishing pigs between 8 and 16 weeks of age are most commonly affected, though pigs of any age can develop disease.

The economic impact of APP extends across multiple dimensions of swine production. Acute outbreaks cause direct mortality losses that can be substantial in severely affected herds. Subclinical and chronic infections result in reduced feed efficiency, decreased daily gain, and increased time to market weight. Carcass condemnations due to pleurisy and lung lesions at slaughter represent additional economic losses. Treatment costs including antimicrobials and veterinary care, combined with prevention expenses for vaccination programs, add to the overall financial burden of this disease.

Management of APP requires a comprehensive approach combining biosecurity, vaccination, strategic antimicrobial use, and environmental optimization. While treatments can effectively address acute outbreaks, preventing introduction of virulent strains and maintaining stable herd immunity represent the cornerstones of long-term control. Advances in diagnostic methods, vaccine development, and understanding of disease pathogenesis continue to improve the industry's ability to manage this challenging respiratory pathogen.

Actinobacillus pleuropneumoniae is a gram-negative, encapsulated, facultatively anaerobic bacterium belonging to the family Pasteurellaceae. The organism is classified into 19 recognized serovars based on capsular polysaccharide and lipopolysaccharide antigens, with virulence varying significantly among serovars. Serovars 1, 5, 9, 10, and 11 are generally considered most virulent in North America, while serovars 2 and 9 predominate in Europe. Two biotypes exist: biotype 1 is NAD-dependent and associated with most clinical disease, while biotype 2 is NAD-independent and less commonly pathogenic.

Transmission of APP occurs primarily through direct contact with infected pigs, with the respiratory route being the most important means of spread. The organism is shed in nasal secretions from infected animals, and susceptible pigs become infected through inhalation of bacteria-containing aerosols or direct nose-to-nose contact. Carrier pigs that harbor the organism in their tonsils without showing clinical signs serve as ongoing sources of infection within herds. Short-distance airborne transmission within buildings allows rapid spread among penmates and can facilitate disease movement between rooms or barns.

Environmental conditions and management factors significantly influence APP transmission and disease expression. Overcrowding increases contact rates and aerosol concentration, promoting bacterial spread. Poor ventilation leads to accumulation of ammonia and particulates that damage respiratory defenses and enhance pathogen colonization. Temperature fluctuations, drafts, and high humidity stress animals and compromise immune function. Mixing of pigs from different sources introduces naive animals to endemic strains and brings potentially different serovars into contact with susceptible populations.

Risk factors predisposing to APP outbreaks include introduction of infected carrier animals, environmental stressors, concurrent respiratory infections, and immune status of the herd. Co-infections with Mycoplasma hyopneumoniae, PRRS virus, swine influenza, and other respiratory pathogens predispose to more severe APP disease through damage to respiratory defenses. Young pigs that have lost maternally-derived immunity but have not yet developed active immunity are particularly vulnerable. Stressful events such as transportation, weaning, and mixing precipitate disease in colonized animals.

The pathogenesis of APP involves adhesion to respiratory epithelium followed by production of potent toxins that damage host tissue and evade immune defenses. The organism produces several RTX toxins (ApxI, ApxII, ApxIII, and ApxIV) with hemolytic and cytotoxic properties that cause the characteristic lung damage. ApxI is strongly hemolytic and cytotoxic, while ApxII is weakly hemolytic but moderately cytotoxic. The capsule provides resistance to phagocytosis and complement-mediated killing. Lipopolysaccharide contributes to inflammation and systemic effects. The combination of tissue-damaging toxins and inflammatory responses produces the severe hemorrhagic necrotizing pneumonia characteristic of acute APP.

Early warning signs of APP infection may be subtle and easily overlooked before acute disease develops. Mild lethargy and decreased feed intake may precede more severe clinical signs by hours to days. Slightly elevated respiratory rate and occasional coughing may be noticed in some animals. Body temperature may be mildly elevated during early infection. These prodromal signs are often recognized only in retrospect after acute disease has developed in pen mates or building mates.

Acute APP presents with dramatic clinical signs that develop rapidly and can result in death within hours. Affected pigs develop severe respiratory distress characterized by open-mouth breathing, marked dyspnea, and cyanosis of the ears, snout, and extremities. Body temperature rises sharply, often exceeding 41°C (106°F). Pigs assume a dog-sitting position or lie in sternal recumbency with extended neck in attempts to ease breathing. Frothy blood-tinged discharge from the nose and mouth may be observed in severe cases. Death can occur within 12 to 36 hours of onset in peracute cases, sometimes before significant clinical signs are recognized.

Behavioral changes in APP-affected pigs reflect severe respiratory compromise and systemic illness. Affected animals separate from penmates, often seeking cooler areas of the pen near waterers or under ventilation inlets. Complete anorexia develops with refusal of both feed and water in acute cases. Pigs resist movement and handling, as activity exacerbates respiratory distress. When forced to move, affected animals show extreme reluctance and may collapse. Mortality during acute outbreaks typically concentrates among the fastest-growing, highest-performing pigs in affected groups.

Physical examination findings in APP cases include high fever, tachypnea, harsh lung sounds on auscultation, and evidence of consolidation in ventral lung lobes. Cyanosis is particularly evident on the ears, which may appear blue-purple in color. Muffled heart sounds may be detected when pericardial effusion develops. Palpation of the thorax may elicit pain responses. Skin may feel cool and clammy in animals developing cardiovascular shock. Mouth breathing with extended head and neck position is characteristic of severe respiratory compromise.

Symptom progression in untreated cases typically involves rapid deterioration from initial respiratory signs to severe dyspnea, cardiovascular collapse, and death. Animals surviving the acute phase may develop chronic infection characterized by persistent coughing, reduced growth rate, and poor feed efficiency. Chronic cases may show no obvious clinical signs beyond decreased performance, though lung lesions continue to affect respiratory function. Some animals become asymptomatic carriers that harbor bacteria in tonsillar tissue and maintain the potential for transmission.

Emergency symptoms requiring immediate intervention include sudden death of previously healthy pigs, clustering of severe respiratory distress cases, blood-tinged nasal discharge, and cyanosis with labored breathing. Multiple deaths within a pen or building over a short time period (hours to days) strongly suggests acute APP outbreak. Any sudden increase in mortality among growing or finishing pigs, particularly when preceded by respiratory signs, warrants immediate veterinary investigation and initiation of treatment protocols before losses escalate further.

Clinical diagnosis of APP is based on characteristic history, clinical presentation, and gross pathological findings. The sudden onset of severe respiratory disease with high fever, cyanosis, and rapid mortality in growing pigs is highly suggestive of acute APP. Post-mortem examination reveals distinctive lesions including well-demarcated hemorrhagic and necrotic lung lesions, fibrinous pleuritis with adhesions between lung and chest wall, and bloodstained fluid in the thoracic cavity. These gross findings, particularly in acute cases, are often sufficiently characteristic to permit presumptive diagnosis pending laboratory confirmation.

Laboratory diagnosis confirms APP infection and provides valuable information about the infecting serovar. Bacterial culture from fresh lung tissue, pleural fluid, or tonsillar swabs enables isolation and identification of the organism. Antimicrobial susceptibility testing of isolates guides treatment decisions and identifies resistance patterns. Serotyping of isolates determines which of the 19 serovars is involved, which has implications for vaccine selection and epidemiological investigation. Newer molecular methods including PCR can rapidly detect and identify APP directly from clinical samples.

Serological testing detects antibodies against APP and provides information about herd exposure status. ELISA tests can detect antibodies against specific serovars or common antigens shared across serovars. Serological testing is particularly useful for herd-level surveillance, monitoring vaccination responses, and investigating exposure patterns. However, antibodies persist following infection and vaccination, so serology cannot distinguish current from past infection. Serological profiles within herds help characterize endemic status and guide management decisions.

Differential diagnosis for APP includes other causes of acute respiratory disease and sudden death in growing pigs. Swine influenza can cause acute respiratory outbreaks with similar initial presentation, though mortality is typically lower. Pasteurella multocida pneumonia may present similarly but usually lacks the hemorrhagic character of APP lesions. Glässer's disease (Haemophilus parasuis) causes polyserositis that may involve the pleura and requires differentiation. Acute PRRS can cause respiratory disease and mortality, though the hemorrhagic pneumonia is not characteristic. Thorough necropsy examination and laboratory testing differentiate these conditions from APP.

Emergency treatment for acute APP requires rapid initiation of antimicrobial therapy to prevent mortality in affected animals and limit spread within the population. Injectable antimicrobials providing rapid, high tissue concentrations are essential for treating clinically ill animals. Ceftiofur, florfenicol, enrofloxacin, tulathromycin, and tiamulin represent commonly effective options, though susceptibility testing should guide selection when possible. Treatment should be initiated immediately upon recognition of disease rather than waiting for laboratory confirmation, as delays of even hours can result in additional deaths.

Medical management following emergency stabilization involves continued antimicrobial therapy and supportive care. Injectable treatments may be continued for 3 to 5 days in severely affected individuals. Transition to oral or water medication provides sustained antimicrobial coverage for in-contact animals at risk of developing disease. Anti-inflammatory drugs such as meloxicam or flunixin may provide symptomatic relief and reduce inflammation, though their impact on outcomes is not well established. All treatments in food-producing animals must observe appropriate withdrawal times before slaughter.

Supportive care measures optimize conditions for recovery and reduce stress on affected animals. Reducing stocking density by removing recovered or unaffected animals relieves competition for resources and reduces aerosol transmission. Optimizing ventilation improves air quality without creating drafts that stress animals. Providing easily accessible water and palatable feed encourages intake in recovering animals. Hospital pens allow individualized care for severely affected pigs. Temperature management ensures thermal comfort during the recovery period.

Herd treatment protocols address the population-level nature of APP outbreaks. Water medication with appropriate antimicrobials provides treatment to in-contact animals that may be incubating disease. Feed medication offers sustained coverage but requires that animals continue eating, which may not occur in acutely ill individuals. Strategic medication timing during high-risk periods (weaning, mixing, weather changes) may reduce outbreak severity. Treatment protocols should be developed in consultation with the herd veterinarian based on farm-specific disease patterns and antimicrobial susceptibility data.

Prevention of future outbreaks begins during the treatment period and involves evaluation of contributing factors. Assessment of ventilation, stocking density, and management practices identifies modifiable risk factors. Vaccination programs should be reviewed and adjusted based on outbreak characteristics. Biosecurity evaluation identifies potential sources of virulent strain introduction. Development of an integrated control program addressing multiple contributing factors provides the best protection against recurrence.

Treatment decision factors in commercial swine production balance individual animal welfare with economic and practical considerations. Severely affected animals with poor prognosis may be candidates for humane euthanasia rather than prolonged treatment with uncertain outcomes. Cost-benefit analysis of treatment protocols considers drug costs, labor, and probability of favorable outcomes. Investment in prevention measures often proves more economically efficient than relying solely on treatment to control APP. Veterinary guidance helps producers navigate these complex decisions effectively.

Recovery timeline for individual pigs surviving acute APP varies based on disease severity and treatment timing. Animals treated early in the disease course may show clinical improvement within 24 to 48 hours and return to normal feed consumption within 3 to 5 days. More severely affected pigs may require 1 to 2 weeks of supportive care before returning to normal behavior. Lung damage sustained during infection may permanently affect respiratory capacity and growth performance even in clinically recovered animals. Some survivors develop chronic infection with persistent lung lesions.

Post-treatment monitoring involves observation for relapse and assessment of recovery progress. Recovered animals should be monitored for recurrence of respiratory signs that could indicate treatment failure or reinfection. Feed consumption and growth rate provide objective measures of recovery and return to normal function. Animals showing poor recovery or continued clinical signs may require extended treatment or euthanasia decisions. Monitoring of in-contact animals identifies new cases developing despite treatment efforts.

Prognosis for individual survival depends on disease stage at treatment initiation and disease severity. Pigs treated during the earliest stages of infection have good prognosis for survival and return to productivity. Delayed treatment of acute cases carries guarded prognosis, as lung damage may be extensive before antimicrobials can control bacterial proliferation. Chronic cases typically survive but show compromised performance and may have carcass quality issues at slaughter. The fastest-growing, highest-value pigs are often most severely affected and may have poorer outcomes than slower-growing penmates.

Return to production considerations following APP outbreaks include assessment of lung damage through slaughter checks and growth performance monitoring. Pleurisy scores at slaughter correlate with historic respiratory disease and predict economic impacts. Calculating close-out performance for affected groups quantifies growth rate and feed efficiency impacts. Comparison of affected versus unaffected contemporaries documents outbreak costs. These data inform management decisions about prevention investments and future disease control strategies.

Vaccination against APP represents a key component of prevention programs, though vaccines provide incomplete protection due to serovar diversity and virulence factor variation. Commercial bacterin vaccines typically contain one or more serovars selected for regional prevalence and cross-protection potential. Subunit vaccines targeting APX toxins provide broader cross-protection across serovars but may not prevent colonization. Autogenous vaccines prepared from farm-specific isolates address limitations of commercial products when endemic strains are poorly matched. Vaccination timing typically targets gilts before breeding and piglets before the high-risk growing period.

Biosecurity measures prevent introduction of new APP strains and reduce transmission within herds. External biosecurity includes sourcing replacement animals from known low-prevalence herds, quarantine and testing of incoming stock, and control of visitors and vehicle traffic. Gilt acclimation programs ensure replacements develop immunity to endemic strains before entering the breeding herd. Within-herd biosecurity involves all-in-all-out management, cleaning and disinfection between groups, and minimizing mixing of animals from different sources.

Environmental management reduces stress and optimizes respiratory health to minimize APP disease expression. Ventilation systems should maintain appropriate temperature, minimize temperature fluctuations, and provide adequate air exchange to reduce ammonia and dust levels. Stocking densities within recommended ranges reduce contact rates and improve air quality per pig. Thermal comfort through appropriate heating, cooling, and bedding reduces stress-related immunosuppression. Attention to these environmental factors is particularly important during high-risk periods including weaning and the transition to grow-finish facilities.

Strategic medication programs may reduce APP disease in high-risk populations or during high-risk periods. Prophylactic or metaphylactic antimicrobial administration around weaning or entry to finishing facilities can reduce clinical disease during vulnerable periods. Feed or water medication provides population-level coverage when disease pressure is high. However, antimicrobial stewardship concerns favor prevention through vaccination and management over routine medication. Strategic medication should be part of comprehensive programs rather than the sole prevention approach.

Quarantine and testing protocols for incoming animals help prevent introduction of virulent APP strains into herds with low disease pressure. Isolation of new arrivals for observation and testing identifies potentially infected animals before introduction to the main herd. Serological testing provides information about exposure history but cannot detect carriers definitively. PCR testing of tonsillar swabs offers more direct detection of colonization. Length of quarantine and testing requirements should be proportional to risk based on source herd status and biosecurity level.

Daily management and monitoring in herds with APP history or risk requires vigilance for early disease detection. Personnel should observe animals daily for respiratory signs including coughing, labored breathing, and changes in posture suggesting respiratory discomfort. Feed consumption monitoring detects decreases that may precede clinical disease. Mortality patterns should be tracked and investigated promptly, with necropsy of dead pigs helping to identify causes and guide response. Communication systems ensure rapid notification of veterinary personnel when problems are detected.

Housing and environmental management directly impact APP transmission and disease severity. Barn design should facilitate all-in-all-out management with complete cleanout between groups. Ventilation systems require regular maintenance and adjustment to maintain optimal air quality across seasons and production stages. Temperature monitoring and control systems help minimize thermal stress. Flooring design and maintenance affect hygiene and air quality through manure management. Investment in housing infrastructure pays dividends through reduced respiratory disease.

Herd health programs addressing APP integrate surveillance, vaccination, medication strategies, and management practices. Regular serological monitoring tracks herd exposure status and vaccination responses. Slaughter surveillance through lung scoring and pleurisy evaluation provides information about subclinical disease burden. Production data analysis identifies groups or periods with elevated disease risk. Veterinary review of program effectiveness and adjustment based on results ensures continued optimization of control measures.

Record keeping supports disease management through documentation of health events, treatments, and outcomes. Production records by group enable identification of patterns and risk factors. Treatment records ensure compliance with withdrawal times and support antimicrobial stewardship efforts. Mortality records with necropsy findings build understanding of disease patterns over time. Vaccination documentation confirms protocol compliance and enables correlation with outcomes. Integrated data systems facilitate analysis and inform management decisions.

Economic considerations in APP management include costs of prevention versus losses from disease. Calculating costs of vaccination, environmental improvements, and management changes enables comparison with documented disease losses. Return on investment analysis guides prioritization of prevention expenditures. Mortality costs, treatment expenses, and performance impacts contribute to total disease cost calculations. Working with veterinarians and production advisors helps producers develop economically optimized control strategies.

All commercial breeds and genetic lines of domestic swine are susceptible to Actinobacillus pleuropneumoniae infection, with no breeds demonstrating natural resistance. The disease affects pigs across the genetic spectrum from heritage breeds in extensive systems to modern high-lean commercial genetics in intensive production. While genetic differences in immune responsiveness may influence individual outcomes, breed is not a significant determinant of herd-level disease risk compared to management and environmental factors.

Production type and management system significantly influence APP risk and impact. Intensive finishing operations with high stocking densities and multiple-source pig flows face elevated disease pressure. Continuous-flow facilities where pigs of different ages and sources share airspace experience ongoing transmission. All-in-all-out systems with strict biosecurity have better ability to break transmission cycles. Outdoor and extensive systems may have lower APP pressure due to reduced stocking density and improved air quality, though the disease can occur in any production system.

Genetic selection for disease resistance has not focused specifically on APP, though selection for overall robustness and immune competence may provide indirect benefits. High-health nucleus and multiplier herds maintain freedom from APP and other pathogens through biosecurity rather than genetic resistance. Breeding companies do not typically offer APP-resistant genetic lines. Producers should address APP risk through management, biosecurity, and vaccination rather than expecting genetic solutions to provide protection.

Commonly co-occurring conditions with APP include other components of the porcine respiratory disease complex. Mycoplasma hyopneumoniae often precedes or accompanies APP infection, with mycoplasmal damage to respiratory defenses predisposing to more severe APP disease. PRRS virus co-infection is extremely common and significantly worsens respiratory disease outcomes. Swine influenza virus may occur in the same populations and contributes to respiratory disease burden. Pasteurella multocida frequently acts as secondary invader in APP-affected lungs. This polymicrobial nature of swine respiratory disease makes comprehensive diagnostic evaluation essential.

Conditions with similar clinical presentations requiring differentiation include other causes of acute respiratory disease and sudden death in growing pigs. Glässer's disease (Haemophilus parasuis) causes polyserositis that may mimic APP when pleural involvement predominates. Pasteurella multocida bronchopneumonia can present with acute respiratory disease, though the hemorrhagic character of APP is usually absent. Acute PRRS may cause respiratory disease with mortality in growing pigs. Swine influenza causes herd-level respiratory outbreaks with high morbidity but typically lower mortality than APP. Necropsy findings and laboratory testing differentiate these conditions.

Complications and sequelae of APP infection include development of chronic respiratory disease, lung abscesses, and pleurisy with adhesions that affect carcass quality. Chronic carriers may show reduced growth performance throughout the finishing period without obvious clinical signs. Lung lesions detected at slaughter indicate subclinical disease impacts and provide useful surveillance information. Pleurisy adhesions result in trimming and carcass value reduction. Severe cases may develop pericarditis or other manifestations of systemic disease spread.